Organ support & nutrition

High-dose intravenous vitamin C reduce C-reactive protein levels, fluid retention, and APACHE II scores in patients with moderately severe acute pancreatitis: a prospective, randomized, double-blinded, placebo-controlled study

Ann Intensive CarePublished Randomised controlled trial

Primary result · 28-day mortalityResult — go to the resultUnadjusted odds ratio 0.70 95% CI 0.15–3.21
  • terminated prematurely

Authors' conclusion

HDIVC did not significantly reduce 28-day mortality in MSAP and SAP patients.

Study context

Population
Adults with predicted moderately severe (moderately severe acute pancreatitis (MSAP)) or severe acute pancreatitis (SAP) within 72 h of symptom onset155 MSAP, 57 SAP
Participants
212 adults
Comparison
High-dose IV vitamin C vs matched placebo for 7 days
  • High-dose intravenous vitamin C (HDIVC)n = 109
  • Controln = 103reference
Primary endpoint
28-day mortality
Follow-up
28 days
Methodological detailsdouble-blinded, placebo-controlled, Enrolled September 2019 to June 2023
  • Double-blinded
  • Placebo-controlled
  • Enrolled September 2019 to June 2023

Primary result

As reported in the abstract

Unadjusted odds ratio

0.70

95% CI 0.15–3.21

P = 0.647

Events by treatment group

HDIVC

3 of 109

3 of 109

Control

4 of 103

4 of 103

HDIVC vs Control
unadjusted OR 0.70 (95% CI 0.15–3.21); P = 0.647

Further findings

Fluid retention volume, MSAP (subgroup) · Day0-Day1

P = 0.04

Fluid retention volume, MSAP (subgroup) · Day0-Day2

P = 0.02

Fluid retention volume, MSAP (subgroup) · Day0-Day3

P = 0.04

OutcomeHDIVCControlP value
CRP reduction, MSAP (subgroup) · Day0 to Day3Median, mg/L7246P = 0.003
CRP reduction, MSAP (subgroup) · Day0 to Day7Median, mg/L168121P = 0.013
APACHE II score reduction, MSAP (subgroup) · Day0 to Day7Median32P = 0.01

SAP (subgroup)

No significant difference among patients with SAP

Original publication

High-dose intravenous vitamin C reduce C-reactive protein levels, fluid retention, and APACHE II scores in patients with moderately severe acute pancreatitis: a prospective, randomized, double-blinded, placebo-controlled study. Ann Intensive Care. Published 17 March 2025. doi:10.1186/s13613-025-01437-z

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.